Algorae Pharmaceuticals (ASX:1AI): Pharmaceutical Agreements, AI Research and FY26 Results

Aditi Sarkar

23 October 2026 04:27 PM AEDT

Algorae Pharmaceuticals (ASX:1AI): Pharmaceutical Agreements, AI Research and FY26 Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Algorae Pharmaceuticals (ASX:1AI) expanded its medicine licensing arrangements during 2026.
FY26 revenue and other income totalled AUD 77,667, while the net loss was AUD 2.71 million.
Its June-quarter report recorded AUD 3.94 million in cash and an undrawn AUD 3 million facility.
October announcements addressed a Umedica supply agreement and a third AI validation program.

Algorae Pharmaceuticals Limited develops AI-assisted drug-combination research programs and commercialises generic and specialty medicines for Australia and New Zealand. At the time of writing on 23 October 2026, Algorae Pharmaceuticals (ASX:1AI) was quoted at AUD 0.009, down 10.00% for the trading session. Recent developments include new pharmaceutical supply agreements, independent research validation work and FY26 results reflecting ongoing operating expenditure.

Company Business

Algorae Pharmaceuticals (ASX:1AI) operates AlgoraeRx and AlgoraeOS. AlgoraeRx sources generic and specialty medicines, negotiates licensing and supply agreements, manages regulatory registrations and targets institutional distribution in Australia and New Zealand. Its therapeutic categories include oncology, cardiovascular, metabolic and specialty care.

AlgoraeOS analyses potential combinations of existing and investigational medicines. Computational results guide laboratory candidate selection rather than demonstrate clinical efficacy. Australian research collaborations support validation, while AI-116 and AI-168 remain preclinical programs.

Recent Development

In October 2026, Algorae Pharmaceuticals (ASX:1AI) announced that it had executed a licence and supply agreement with Umedica. The announcement added to the company’s program of sourcing pharmaceutical products for eventual distribution, subject to applicable commercial and regulatory steps. A separate October announcement described a third artificial intelligence validation program with the Peter MacCallum Cancer Centre, extending the company’s laboratory evaluation of predicted drug combinations.

Its June 2026 quarterly report documented five AlgoraeRx commercial agreements, including a 10-product agreement with Zydus. The Therapeutic Goods Administration accepted Stage 1 dossiers for two of three submitted products for evaluation; acceptance is not approval.

AlgoraeOS version 2 analysed more than nine million potential combinations spanning 18 anchor drugs. Screening identified over 478,000 predictions passing thresholds and over 6,000 multi-cell-line combinations with predicted synergy. These are computational findings, not approved treatments.

Financial Performance and Sector Context

Algorae Pharmaceuticals (ASX:1AI) reported FY26 total revenue and other income of AUD 77,667, compared with a higher amount in FY25, representing a 45% decrease. Its net loss after tax was AUD 2.71 million, compared with a smaller loss in the previous financial year. The FY26 loss before income tax was AUD 3.10 million. The results reflect a business investing in registrations, development and commercial operations rather than reporting substantial recurring pharmaceutical sales.

The company’s quarter ended 30 June 2026 showed a cash balance of AUD 3.94 million. Its Appendix 4C identified a separate AUD 3.0 million receivables facility that remained fully undrawn, giving reported total available funding of AUD 6.94 million at that date. A facility is a potential funding source subject to its terms and should not be treated as cash already held.

An April 2026 capital raising delivered approximately AUD 3.99 million before costs through option exercises and shortfall placement shares. Regulatory evaluations, manufacturing, procurement and distribution remain important to eventual medicine sales.

Risks to Consider

Algorae Pharmaceuticals (ASX:1AI) faces regulatory approval, sourcing, working-capital and inventory risks. Supply agreements may not immediately generate sales. AI-generated predictions need laboratory and potentially clinical validation. Operating losses, research costs and future financing requirements also warrant attention.

What to Watch Next

For Algorae Pharmaceuticals (ASX:1AI), milestones include TGA evaluations, product availability and evidence of pharmaceutical sales. Upcoming quarterly cash reports will clarify funding and operating expenditure. Further independent laboratory testing and candidate selection remain relevant to AlgoraeOS.

October’s licensing and validation announcements represent different stages of development, not established sales or clinical success.

Key Insights

Algorae’s FY26 financial results recorded limited revenue and a net loss, alongside the development of its pharmaceutical supply business. Its June-quarter disclosure identified five commercial agreements, regulatory dossier activity and a cash position supplemented by an undrawn facility. For Algorae Pharmaceuticals (ASX:1AI), subsequent reporting will clarify medicine registrations, product supply, research verification and funding requirements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.